JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27

Benzinga Newsdesk www.benzinga.com Neutral 55.3%

Neg 0% Neu 55.3% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.